content: <PAGE>
                                   FORM 8-K
   
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, DC   20549
  
                                  CURRENT REPORT
  
                        Pursuant to Section 13 or 15(d) of
                       The Securities Exchange Act of 1934
  
  
  DATE OF REPORT (Date of earliest event reported):  July 26, 1996
  
  
                FUTURE MEDICAL TECHNOLOGIES INTERNATIONAL, INC.
            (Exact name of registrant as specified in its charter)
  
  
  
           Nevada                     33-43537            56-1668867
       (State or other             (Commission         (IRS Employer
       jurisdiction of              File Number)     Identification No.)
       incorporation)
  
  
                          One Glenhardie Corporate Center
                          1275 Drummers Lane, Suite 201
                                 Wayne, PA. 19087
                     (Address of Principal Executive Offices)
            
                  Registrant's telephone number:  (610) 975-9533
  
  
  <PAGE>
                                     FORM 8-K
  
  
  ITEM 1.  CHANGES IN CONTROL OF REGISTRANT
  
  Not applicable.
  
  ITEM 2.  ACQUISITION OR DISPOSITION OF ASSETS
  
  Since the Company's Future Medical Technologies, Inc. ("FMT")
  subsidiary requires substantial funds for research and development
  from investment at this time in order to fully develop its business,
  the Registrant entered into a Letter of Intent with Medical
  Technologies, Inc. ("MTI") for the disposition of FMT on July 26,
  1996.  On August 20, 1996, the transaction was finalized, subject to
  shareholder approval.  The Board of Directors of the Registrant has
  decided that because of its limited cash resources, that the
  Registrant would be better served to spend its resources on its other
  divisions.  Accordingly, the Registrant desires to sell its 100%
  interest in FMT in order to avoid having to put further investment
  funds in FMT and to stop the substantial reduction of earnings in the
  consolidated financials that is adversely affecting the Registrant
  ($110,000 FMT loss in second quarter, 1996 alone). 
  
  A new corporation, MTI, has put together an investment group including
  John Figliolini a shareholder of the Registrant that is willing to
  invest $500,000 in MTI that will purchase 100% of the stock of FMT
  from the Registrant thereby allowing FMT to continue as a separate
  operating entity with at least sufficient working capital to provide
  R&D and operating expenses to further exploit FMT technologies.  
  
  The Board of Directors of the Registrant has voted to accept this
  proposal of sale subject to receipt of a "Fairness Opinion" prepared
  by a NASD broker in good standing, and subject to a Shareholder vote
  of the Registrant, as soon as practical.  The Board has received such
  a "Fairness Opinion" from the Shamrock Partners Ltd. in Media, PA
  which can be viewed at the Registrant's offices (which is primarily
  based on the information above).  The sales price is $250,000, $25,000
  down and the balance over the next four years with interest at the
  rate of 7% per annum.  
  
  Additional consideration would be a license fee on all gross revenues
  (less returns) earned by the Buyer's corporation and FMT derived from
  any sale of the "Dehydrated Media Paddle", "Qualture", "Salmonella"
  (net gross revenues) (XLT4 Media as licensed from the University of
  Maryland) all as described in the Form 10-KSB for year ended December
  31, 1995, as well as any modifications of same (the "FMT technology"):
  5% for the first and second years;  2 1/2% for the third, fourth and
  fifth years.  All such license payments will cease at the end of the
  fifth year.
  <PAGE>
  In addition, Joseph Hippensteel and Deanne VanLeeuwen, officers of FMT
  agreed to donate back to the Registrant one half of their 570,000 and
  380,000 stock options (expiring March 22, 2000 at the exercise price
  of $2.875 per share), respectively.  Pending Shareholder approval, the
  Buyer is operating FMT as of August 20, 1996 with the appropriate
  adjustments to be made in the event Shareholder approval is not
  obtained, including reasonable actual reimbursement (capped at
  $50,000) and a penalty of an additional $50,000 if shareholder
  approval is not obtained.  The financial results of this transaction
  would result in a one time non-recurring loss of approximately
  $275,000 in the third quarter.
  
  ITEM 3.  BANKRUPTCY OR RECEIVERSHIP
  
  Not applicable.
  
  ITEM 4.  CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT
  
  Not applicable.
  
  ITEM 5.  OTHER EVENTS
  
  Not applicable.
  
  ITEM 6.  RESIGNATION OF REGISTRANT'S DIRECTORS
  
  On July 26, 1996, Joseph Hippensteel resigned as a Director of the
  Registrant.
  
  ITEM 7.  FINANCIAL STATEMENTS AND EXHIBITS
  
           (c)  Exhibits
  
                1.  Letter of Intent between Medical Technologies, Inc. and
                    the Registrant dated July 26, 1996.
  <PAGE>
                                   SIGNATURES
  
  Pursuant to the requirements of the Securities Exchange Act of
  1934, the Registrant has duly caused this report to be signed on its
  behalf by the undersigned hereunto duly authorized.
  
  
  
                                   FUTURE MEDICAL TECHNOLOGIES
                                   INTERNATIONAL, INC.
  
  
                                   BY:/s/Bruce LaMont
                                      ------------------------------
                                      Bruce LaMont, President       
  
  
  FMTI\072696.8-K
metadata_documents: [{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 5417}]
metadata_filer: {"company-data": {"conformed-name": "FUTURE MEDICAL TECHNOLOGIES INTERNATIONAL INC", "cik": "0000856569", "assigned-sic": "3826", "irs-number": "561668867", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-21145", "film-number": "96619356"}, "business-address": {"street1": "ONE GLENHARDIE CORPORATE CENTER", "street2": "1275 DRUMMERS LANE STE 201", "city": "WAYNE", "state": "PA", "zip": "19087", "phone": "6109759533"}, "mail-address": {"street1": "ONE GLENHARDIE CORPORATE CENTER", "street2": "1275 DRUMMERS LANE STE 201", "city": "WAYNE", "state": "PA", "zip": "19087"}}
text: FORM 8-K
   
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, DC   20549
  
                                  CURRENT REPORT
  
                        Pursuant to Section 13 or 15(d) of
                       The Securities Exchange Act of 1934
  
  DATE OF REPORT (Date of earliest event reported):  July 26, 1996
  
                FUTURE MEDICAL TECHNOLOGIES INTERNATIONAL, INC.
            (Exact name of registrant as specified in its charter)
  
           Nevada                     33-43537            56-1668867
       (State or other             (Commission         (IRS Employer
       jurisdiction of              File Number)     Identification No.)
       incorporation)
  
                          One Glenhardie Corporate Center
                          1275 Drummers Lane, Suite 201
                                 Wayne, PA. 19087
                     (Address of Principal Executive Offices)
            
                  Registrant's telephone number:  (610) 975-9533
  FORM 8-K
  
  ITEM 1.  CHANGES IN CONTROL OF REGISTRANT
  
  Not applicable.
  
  ITEM 2.  ACQUISITION OR DISPOSITION OF ASSETS
  
  Since the Company's Future Medical Technologies, Inc. ("FMT")
  subsidiary requires substantial funds for research and development
  from investment at this time in order to fully develop its business,
  the Registrant entered into a Letter of Intent with Medical
  Technologies, Inc. ("MTI") for the disposition of FMT on July 26,
  1996.  On August 20, 1996, the transaction was finalized, subject to
  shareholder approval.  The Board of Directors of the Registrant has
  decided that because of its limited cash resources, that the
  Registrant would be better served to spend its resources on its other
  divisions.  Accordingly, the Registrant desires to sell its 100%
  interest in FMT in order to avoid having to put further investment
  funds in FMT and to stop the substantial reduction of earnings in the
  consolidated financials that is adversely affecting the Registrant
  ($110,000 FMT loss in second quarter, 1996 alone). 
  
  A new corporation, MTI, has put together an investment group including
  John Figliolini a shareholder of the Registrant that is willing to
  invest $500,000 in MTI that will purchase 100% of the stock of FMT
  from the Registrant thereby allowing FMT to continue as a separate
  operating entity with at least sufficient working capital to provide
  R&D and operating expenses to further exploit FMT technologies.  
  
  The Board of Directors of the Registrant has voted to accept this
  proposal of sale subject to receipt of a "Fairness Opinion" prepared
  by a NASD broker in good standing, and subject to a Shareholder vote
  of the Registrant, as soon as practical.  The Board has received such
  a "Fairness Opinion" from the Shamrock Partners Ltd. in Media, PA
  which can be viewed at the Registrant's offices (which is primarily
  based on the information above).  The sales price is $250,000, $25,000
  down and the balance over the next four years with interest at the
  rate of 7% per annum.  
  
  Additional consideration would be a license fee on all gross revenues
  (less returns) earned by the Buyer's corporation and FMT derived from
  any sale of the "Dehydrated Media Paddle", "Qualture", "Salmonella"
  (net gross revenues) (XLT4 Media as licensed from the University of
  Maryland) all as described in the Form 10-KSB for year ended December
  31, 1995, as well as any modifications of same (the "FMT technology"):
  5% for the first and second years;  2 1/2% for the third, fourth and
  fifth years.  All such license payments will cease at the end of the
  fifth year.
  In addition, Joseph Hippensteel and Deanne VanLeeuwen, officers of FMT
  agreed to donate back to the Registrant one half of their 570,000 and
  380,000 stock options (expiring March 22, 2000 at the exercise price
  of $2.875 per share), respectively.  Pending Shareholder approval, the
  Buyer is operating FMT as of August 20, 1996 with the appropriate
  adjustments to be made in the event Shareholder approval is not
  obtained, including reasonable actual reimbursement (capped at
  $50,000) and a penalty of an additional $50,000 if shareholder
  approval is not obtained.  The financial results of this transaction
  would result in a one time non-recurring loss of approximately
  $275,000 in the third quarter.
  
  ITEM 3.  BANKRUPTCY OR RECEIVERSHIP
  
  Not applicable.
  
  ITEM 4.  CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT
  
  Not applicable.
  
  ITEM 5.  OTHER EVENTS
  
  Not applicable.
  
  ITEM 6.  RESIGNATION OF REGISTRANT'S DIRECTORS
  
  On July 26, 1996, Joseph Hippensteel resigned as a Director of the
  Registrant.
  
  ITEM 7.  FINANCIAL STATEMENTS AND EXHIBITS
  
           (c)  Exhibits
  
                1.  Letter of Intent between Medical Technologies, Inc. and
                    the Registrant dated July 26, 1996.
  SIGNATURES
  
  Pursuant to the requirements of the Securities Exchange Act of
  1934, the Registrant has duly caused this report to be signed on its
  behalf by the undersigned hereunto duly authorized.
  
                                   FUTURE MEDICAL TECHNOLOGIES
                                   INTERNATIONAL, INC.
  
                                   BY:/s/Bruce LaMont
                                      ------------------------------
                                      Bruce LaMont, President       
  
  FMTI\072696.8-K